Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

3 Things Deutsche Bank Likes About Agilent's Q3, And One Thing To Be Cautious Of

RCZRF

Agilent Technologies Inc (NYSE: A)'s earnings report was strong enough for Deutsche Bank's Dan Leonard to maintain a Buy rating on the stock with a price target boosted from $66 to $68.

Agilent's fiscal third-quarter earnings report highlighted the company's strong end market exposures, product cycles, and suggests margin expansion opportunities are likely moving forward, the analyst said in a research report. In fact, there were three encouraging aspects of the earnings report which also reinforce the bullish case.

3 Encouraging Signs

First, Agilent's C&E (chemical and energy) segment realized its second consecutive quarter of double digit growth, Leonard wrote. The segment saw broad strength across various products and regions.

Second, Agilent's biopharma business also showed a 10 percent sales growth which similarly to C&E marks the second consecutive quarter of double digit growth. The company also said that it isn't seeing any signs of softness in the customer base which also includes the generic side of the business.

Third, Agilent's operating margin of 21.5 percent was "well above" the 20.8 percent rate the analyst was expecting. In fact, Leonard is expecting even more upside to the margin rate and is modeling a 90 basis point expansion moving forward.

tipranks.png

Where To Be Concerned

Finally, Agilent's earnings report wasn't perfect as its organic growth guidance for the fiscal fourth quarter fell short of consensus estimates. However, the "optically conservative growth rate" is due to tougher comps in the biopharma segment and China which grew 16 percent and 27 percent, respectively, in the same quarter a year ago.

Also, the company may have hesitated to "extrapolate forward two consecutive quarters" of double digit growth in Europe.

Bottom line, Agilent's earnings report was "strong all around" and there is plenty of reason to assume the long-term bullish thesis is intact.

At time of publication, shares of Agilent Technologies were up 4.28 percent at $61.91.

Related Links:

5 Things That Stood Out In Another Beat And Raise Quarter From Agilent

8 Stocks To Watch For August 16, 2017
_________
Image Credit: By Matt Perreault (Agilent Technologies) [CC BY-SA 2.0 (http://creativecommons.org/licenses/by-sa/2.0)], via Wikimedia Commons

Latest Ratings for A

Date Firm Action From To
Aug 2017 Jefferies Maintains Buy
Jul 2017 Wells Fargo Upgrades Market Perform Outperform
Jul 2017 Morgan Stanley Maintains Overweight

View More Analyst Ratings for A
View the Latest Analyst Ratings